Dirozalkib (XZP-3621) vs Lorlatinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK / ROS1 · full Non-Small Cell Lung Cancer pipeline

Dirozalkib (XZP-3621)

Marketed by Xuanzhu Biopharmaceutical and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT05204628 · Phase 3 · status unknown

Patients were randomly assigned to XZP-3621 or crizotinib, but the study is open-label rather than blinded, which is a weaker design even though it measures a hard clinical outcome, progression-free survival, against an active standard-of-care comparator. Results have not been posted yet.

No aligned efficacy figure on record for this race.

Lorlatinib

Marketed by Pfizer

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT03052608 · Phase 3 · active, not recruiting

People were randomized to lorlatinib or the active comparator crizotinib and progression-free survival was read by blinded independent review, with a clear significant result in 296 people. The trial was open-label, so participants and investigators knew the treatment.

Next expected readout: December 2026 · NCT05059522 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDirozalkib (XZP-3621)Lorlatinib
PFS, median—Not reported16.6bn 30NCT01970865
11 other results
OS, median—Not reported52.5bn 27NCT01970865
4 other results
ORR—Not reported75.8% vs 57.8%vs Crizotinibn 149NCT03052608
4 other results
Duration of response, median—Not reported20.9bn 26NCT04362072
4 other results

PFS, median

Dirozalkib (XZP-3621)
—Not reported
Lorlatinib
16.6bn 30NCT01970865
11 other results

OS, median

Dirozalkib (XZP-3621)
—Not reported
Lorlatinib
52.5bn 27NCT01970865
4 other results

ORR

Dirozalkib (XZP-3621)
—Not reported
Lorlatinib
75.8% vs 57.8%vs Crizotinibn 149NCT03052608
4 other results

Duration of response, median

Dirozalkib (XZP-3621)
—Not reported
Lorlatinib
20.9bn 26NCT04362072
4 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Dirozalkib (XZP-3621): no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dirozalkib (XZP-3621): 0 of 4 rows · Lorlatinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLorlatinib
Dropout rate
82.6%a
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 22 more results
82.4%100 mg QD
NCT01970865 · Phase 1/2
100%200 mg QD
NCT01970865 · Phase 1/2
100%150 mg QD
NCT01970865 · Phase 1/2
50%100 mg BID
NCT01970865 · Phase 1/2
66.7%75 mg BID
NCT01970865 · Phase 1/2
83.3%75 mg QD
NCT01970865 · Phase 1/2
100%50 mg QD
NCT01970865 · Phase 1/2
100%35 mg BID
NCT01970865 · Phase 1/2
100%25 mg QD
NCT01970865 · Phase 1/2
100%10 mg QD
NCT01970865 · Phase 1/2
40%EXP-1 (Phase 2)
NCT01970865 · Phase 1/2
74.1%EXP-2 (Phase 2)
NCT01970865 · Phase 1/2
70%EXP-3 (Phase 2)
NCT01970865 · Phase 1/2
87.7%EXP-4 (Phase 2)
NCT01970865 · Phase 1/2
93.5%EXP-5 (Phase 2)
NCT01970865 · Phase 1/2
85.1%EXP-6 (Phase 2)
NCT01970865 · Phase 1/2
33.3%Japan Lead-In Cohort (LIC)
NCT01970865 · Phase 1/2
—100mg
NCT04362072 · Phase 4 · registry result, not featured evidence
n/a: no completion milestoneLorlatinib
NCT04362072 · Phase 4 · registry result, not featured evidence
45%100 mg QD
NCT04541706 · Phase 4 · registry result, not featured evidence
n/a: no completion milestoneCohort 1
NCT03909971 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort 2
NCT03909971 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
6.7%a
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 22 more results
—100 mg QD
NCT01970865 · Phase 1/2
—200 mg QD
NCT01970865 · Phase 1/2
—150 mg QD
NCT01970865 · Phase 1/2
—100 mg BID
NCT01970865 · Phase 1/2
—75 mg BID
NCT01970865 · Phase 1/2
—75 mg QD
NCT01970865 · Phase 1/2
—50 mg QD
NCT01970865 · Phase 1/2
—35 mg BID
NCT01970865 · Phase 1/2
—25 mg QD
NCT01970865 · Phase 1/2
—10 mg QD
NCT01970865 · Phase 1/2
—EXP-1 (Phase 2)
NCT01970865 · Phase 1/2
—EXP-2 (Phase 2)
NCT01970865 · Phase 1/2
—EXP-3 (Phase 2)
NCT01970865 · Phase 1/2
—EXP-4 (Phase 2)
NCT01970865 · Phase 1/2
—EXP-5 (Phase 2)
NCT01970865 · Phase 1/2
—EXP-6 (Phase 2)
NCT01970865 · Phase 1/2
—Japan Lead-In Cohort (LIC)
NCT01970865 · Phase 1/2
—100mg
NCT04362072 · Phase 4 · registry result, not featured evidence
1.4%Lorlatinib
NCT04362072 · Phase 4 · registry result, not featured evidence
1%100 mg QD
NCT04541706 · Phase 4 · registry result, not featured evidence
1.5%Cohort 1
NCT03909971 · Phase 2 · registry result, not featured evidence
4.8%Cohort 2
NCT03909971 · Phase 2 · registry result, not featured evidence
Serious AEs
34.2%a
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 22 more results
58.8%100 mg QD
NCT01970865 · Phase 1/2
66.7%200 mg QD
NCT01970865 · Phase 1/2
100%150 mg QD
NCT01970865 · Phase 1/2
50%100 mg BID
NCT01970865 · Phase 1/2
66.7%75 mg BID
NCT01970865 · Phase 1/2
50%75 mg QD
NCT01970865 · Phase 1/2
33.3%50 mg QD
NCT01970865 · Phase 1/2
66.7%35 mg BID
NCT01970865 · Phase 1/2
66.7%25 mg QD
NCT01970865 · Phase 1/2
100%10 mg QD
NCT01970865 · Phase 1/2
50%EXP-1 (Phase 2)
NCT01970865 · Phase 1/2
40.7%EXP-2 (Phase 2)
NCT01970865 · Phase 1/2
56.7%EXP-3 (Phase 2)
NCT01970865 · Phase 1/2
47.7%EXP-4 (Phase 2)
NCT01970865 · Phase 1/2
50%EXP-5 (Phase 2)
NCT01970865 · Phase 1/2
44.7%EXP-6 (Phase 2)
NCT01970865 · Phase 1/2
33.3%Japan Lead-In Cohort (LIC)
NCT01970865 · Phase 1/2
32.4%100mg
NCT04362072 · Phase 4 · registry result, not featured evidence
—Lorlatinib
NCT04362072 · Phase 4 · registry result, not featured evidence
22%100 mg QD
NCT04541706 · Phase 4 · registry result, not featured evidence
34.3%Cohort 1
NCT03909971 · Phase 2 · registry result, not featured evidence
38.1%Cohort 2
NCT03909971 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
hypertriglyceridaemia 52.3%
oedema peripheral 43.6%
blood cholesterol increased 39.6%
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 21 more results
100 mg QD
hypercholesterolaemia 70.6%
oedema peripheral 58.8%
anaemia 41.2%
NCT01970865 · Phase 1/2
200 mg QD
hypercholesterolaemia 100%
affect lability 66.7%
aspartate aminotransferase increased 66.7%
NCT01970865 · Phase 1/2
150 mg QD
anaemia 100%
hypomagnesaemia 100%
oedema peripheral 100%
NCT01970865 · Phase 1/2
100 mg BID
diarrhoea 75%
fatigue 75%
nausea 75%
NCT01970865 · Phase 1/2
75 mg BID
anaemia 66.7%
neuropathy peripheral 66.7%
oedema peripheral 66.7%
NCT01970865 · Phase 1/2
75 mg QD
hypercholesterolaemia 58.3%
blood cholesterol increased 50%
fatigue 41.7%
NCT01970865 · Phase 1/2
50 mg QD
asthenia 66.7%
abdominal pain upper 33.3%
aspartate aminotransferase increased 33.3%
NCT01970865 · Phase 1/2
35 mg BID
dyspnoea 100%
paraesthesia 66.7%
abdominal pain upper 33.3%
NCT01970865 · Phase 1/2
25 mg QD
cough 66.7%
hypercholesterolaemia 66.7%
hypophosphataemia 66.7%
NCT01970865 · Phase 1/2
10 mg QD
oedema peripheral 100%
amylase increased 66.7%
aphasia 66.7%
NCT01970865 · Phase 1/2
hypertriglyceridaemia 76.7%
hypercholesterolaemia 53.3%
oedema peripheral 43.3%
NCT01970865 · Phase 1/2
hypertriglyceridaemia 59.3%
oedema peripheral 55.6%
hypercholesterolaemia 51.9%
NCT01970865 · Phase 1/2
hypertriglyceridaemia 61.7%
hypercholesterolaemia 55%
oedema peripheral 55%
NCT01970865 · Phase 1/2
hypertriglyceridaemia 69.2%
hypercholesterolaemia 58.5%
oedema peripheral 38.5%
NCT01970865 · Phase 1/2
hypertriglyceridaemia 69.6%
hypercholesterolaemia 58.7%
blood cholesterol increased 34.8%
NCT01970865 · Phase 1/2
alanine aminotransferase increased 100%
hypercholesterolaemia 53.2%
hypertriglyceridaemia 53.2%
NCT01970865 · Phase 1/2
blood cholesterol increased 100%
hypertriglyceridaemia 100%
alanine aminotransferase increased 66.7%
NCT01970865 · Phase 1/2
100mg
hypertriglyceridaemia 38%
oedema peripheral 36.6%
hypercholesterolaemia 33.8%
NCT04362072 · Phase 4 · registry result, not featured evidence
100 mg QD
hypertriglyceridaemia 58%
hypercholesterolaemia 57%
weight increased 39%
NCT04541706 · Phase 4 · registry result, not featured evidence
hypertriglyceridaemia 89.6%
weight increased 73.1%
hypercholesterolaemia 61.2%
NCT03909971 · Phase 2 · registry result, not featured evidence
hypertriglyceridaemia 76.2%
hypercholesterolaemia 69%
alanine aminotransferase increased 45.2%
NCT03909971 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 22 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lorlatinib

PFS NA vs 9.3 Crizotinib months
time to event · months
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs 9.1 Crizotinib months
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival NA vs NA Crizotinib months
time to event · months
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 75.8% (n=149) vs 57.8% (n=147) Crizotinib
responder rate · % of participants
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
80.5% (n=149) vs 61.9% (n=147) Crizotinib
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Duration of Response NA vs 11 Crizotinib months
time to event · months
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 90% (n=30)
responder rate · % of participants
No placebo or comparator arm
Objective response
NCT01970865 · Phase 1/2
show 11 more results
74.1% (n=27)
Objective response
NCT01970865 · Phase 1/2
50.8% (n=60)
Objective response
NCT01970865 · Phase 1/2
41.5% (n=65)
Objective response
NCT01970865 · Phase 1/2
34.8% (n=46)
Objective response
NCT01970865 · Phase 1/2
36.2% (n=47)
Objective response
NCT01970865 · Phase 1/2
90% (n=30)
Objective response
NCT01970865 · Phase 1/2
77.8% (n=27)
Objective response
NCT01970865 · Phase 1/2
56.7% (n=60)
Objective response
NCT01970865 · Phase 1/2
40% (n=65)
Objective response
NCT01970865 · Phase 1/2
37% (n=46)
Objective response
NCT01970865 · Phase 1/2
38.3% (n=47)
Objective response
NCT01970865 · Phase 1/2
Intracranial ORR 75% (n=30)
responder rate · % of participants
No placebo or comparator arm
Intracranial objective response
NCT01970865 · Phase 1/2
show 11 more results
58.8% (n=27)
Intracranial objective response
NCT01970865 · Phase 1/2
62.5% (n=60)
Intracranial objective response
NCT01970865 · Phase 1/2
55.6% (n=65)
Intracranial objective response
NCT01970865 · Phase 1/2
39.5% (n=46)
Intracranial objective response
NCT01970865 · Phase 1/2
56% (n=47)
Intracranial objective response
NCT01970865 · Phase 1/2
75% (n=30)
Intracranial objective response
NCT01970865 · Phase 1/2
58.8% (n=27)
Intracranial objective response
NCT01970865 · Phase 1/2
66.7% (n=60)
Intracranial objective response
NCT01970865 · Phase 1/2
53.3% (n=65)
Intracranial objective response
NCT01970865 · Phase 1/2
43.2% (n=46)
Intracranial objective response
NCT01970865 · Phase 1/2
56% (n=47)
Intracranial objective response
NCT01970865 · Phase 1/2
Time to Response 1.4 months
time to event · months
No placebo or comparator arm
TTR
NCT01970865 · Phase 1/2
show 5 more results
1.4 months
TTR
NCT01970865 · Phase 1/2
1.4 months
TTR
NCT01970865 · Phase 1/2
2.6 months
TTR
NCT01970865 · Phase 1/2
1.4 months
TTR
NCT01970865 · Phase 1/2
1.4 months
TTR
NCT01970865 · Phase 1/2
Time to Intra-Cranial Response 2.1 months
time to event · months
No placebo or comparator arm
Intracranial TTR
NCT01970865 · Phase 1/2
show 5 more results
1.4 months
Intracranial TTR
NCT01970865 · Phase 1/2
1.4 months
Intracranial TTR
NCT01970865 · Phase 1/2
1.7 months
Intracranial TTR
NCT01970865 · Phase 1/2
1.4 months
Intracranial TTR
NCT01970865 · Phase 1/2
1.4 months
Intracranial TTR
NCT01970865 · Phase 1/2
Duration of Response 17.16 months
time to event · months
No placebo or comparator arm
DOR
NCT01970865 · Phase 1/2
show 5 more results
16.56 months
DOR
NCT01970865 · Phase 1/2
11.1 months
DOR
NCT01970865 · Phase 1/2
15.08 months
DOR
NCT01970865 · Phase 1/2
7.03 months
DOR
NCT01970865 · Phase 1/2
19.61 months
DOR
NCT01970865 · Phase 1/2
Intracranial Duration of Response NA months
time to event · months
No placebo or comparator arm
Intra-cranial DOR
NCT01970865 · Phase 1/2
show 5 more results
NA months
Intra-cranial DOR
NCT01970865 · Phase 1/2
37.12 months
Intra-cranial DOR
NCT01970865 · Phase 1/2
14.52 months
Intra-cranial DOR
NCT01970865 · Phase 1/2
10.32 months
Intra-cranial DOR
NCT01970865 · Phase 1/2
17.62 months
Intra-cranial DOR
NCT01970865 · Phase 1/2
Disease Control 93.3% (n=30) @ 12wk
responder rate · % of participants
No placebo or comparator arm
Disease control rate at Week 12
NCT01970865 · Phase 1/2
show 5 more results
85.2% (n=27) @ 12wk
Disease control rate at Week 12
NCT01970865 · Phase 1/2
68.3% (n=60) @ 12wk
Disease control rate at Week 12
NCT01970865 · Phase 1/2
64.6% (n=65) @ 12wk
Disease control rate at Week 12
NCT01970865 · Phase 1/2
50% (n=46) @ 12wk
Disease control rate at Week 12
NCT01970865 · Phase 1/2
66% (n=47) @ 12wk
Disease control rate at Week 12
NCT01970865 · Phase 1/2
Disease Control 83.3% (n=30) @ 24wk
responder rate · % of participants
No placebo or comparator arm
Disease control rate at Week 24
NCT01970865 · Phase 1/2
show 5 more results
63% (n=27) @ 24wk
Disease control rate at Week 24
NCT01970865 · Phase 1/2
51.7% (n=60) @ 24wk
Disease control rate at Week 24
NCT01970865 · Phase 1/2
49.2% (n=65) @ 24wk
Disease control rate at Week 24
NCT01970865 · Phase 1/2
32.6% (n=46) @ 24wk
Disease control rate at Week 24
NCT01970865 · Phase 1/2
48.9% (n=47) @ 24wk
Disease control rate at Week 24
NCT01970865 · Phase 1/2

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dirozalkib (XZP-3621)'s landscape · Lorlatinib's landscape